Form 4: GlycoMimetics Director Jonathan Violin Granted Stock Options

GlycoMimetics Inc. Director Jonathan Violin was granted 9,023 stock options with an exercise price of $15.30, vesting based on continued service.

Summary

• Jonathan Violin, a Director of GlycoMimetics Inc. (CBIO), was granted 9,023 stock options on June 23, 2025.
• The stock options have an exercise price of $15.30 per share.
• The options are set to expire on June 23, 2035.
• Vesting for these options will occur in full on the earlier of June 23, 2026, or the date of the Issuer's next annual meeting of shareholders, contingent upon Mr. Violin's continued service to the Issuer.
• Following this transaction, Jonathan Violin directly beneficially owns 9,023 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard compensation practice that aligns the director's interests with shareholders, generally viewed as a neutral to slightly positive event for corporate governance and incentive alignment.

Positives

• The grant of stock options to Director Jonathan Violin aligns his interests with those of shareholders, incentivizing long-term performance and commitment to the company.

Future Outlook

The stock options granted to Director Jonathan Violin are subject to a vesting schedule, indicating an expectation of his continued service to GlycoMimetics Inc. until at least June 23, 2026, or the next annual meeting of shareholders.

Industry Context

This Form 4 filing reflects a routine equity compensation event for a director in the biotechnology or pharmaceutical industry, a common practice to align executive and director incentives with company performance and long-term strategic goals.

Corporate Governance

Related Party Transactions

• The grant of stock options to Jonathan Violin, a Director of GlycoMimetics Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the director's interests with shareholder value creation, potentially leading to improved long-term company performance.

Next Steps

• The stock options will vest on the earlier of June 23, 2026, or the date of the Issuer's next annual meeting of shareholders, subject to continued service.
• Following vesting, the options can be exercised by Jonathan Violin until their expiration date of June 23, 2035.

Key Dates

Keywords

GlycoMimetics, CBIO, Jonathan Violin, Stock Options, Director Compensation, SEC Form 4, Equity Grant, Insider Transaction